m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03207
 [1]
m6A modification HDAC3 HDAC3 IGF2BP3 : m6A sites Direct Enhancement Histone modification Regulated Target HDAC3 Downstream Gene
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
m6A Target Histone deacetylase 3 (HDAC3)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 3 (HDAC3) ERASER View Details
Crosstalk Relationship m6A  →  Histone modification Enhancement
Crosstalk Mechanism m6A modification impacts directly histone modification through modulating the expression level of histone-associated enzymes
Crosstalk Summary METTL14 induced Histone deacetylase 3 (HDAC3) m6A modification in an IGF2BP3-dependent manner, and could activate cGAS-STING pathway through HDAC3.
Responsed Disease Acute ischemic stroke ICD-11: 8B11
 Disease Info 
Pathway Response cGAS-STING signaling pathway hsa:00395
Cell Process Pyroptosis
In-vitro Model
 BV-2 Normal Mus musculus CVCL_0182
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone deacetylase 3 (HDAC3) 19 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name CHR-3996 Phase 1/2 [2]
Synonyms
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7 nM
External Link
CID: 49857317
TTD: D06TKI
DrugBank: DB15419
 Compound Name PMID29671355-Compound-57 Patented [3]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D0UD9R
 Compound Name Diaryl amine derivative 4 Patented [4]
Synonyms
PMID28092474-Compound-9
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
TTD: D0XN2W
 Compound Name PMID29671355-Compound-59 Patented [3]
MOA Inhibitor
Activity IC50 = 43 nM
External Link
CID: 130319551
TTD: D0C9NX
 Compound Name PMID29671355-Compound-55 Patented [3]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
CID: 60198673
TTD: D0OU0J
 Compound Name PMID29671355-Compound-11 Patented [3]
MOA Inhibitor
Activity IC50 = 546 nM
External Link
CID: 118005782
TTD: D0EH2K
 Compound Name PMID29671355-Compound-9 Patented [3]
MOA Inhibitor
Activity IC50 = 158 nM
External Link
CID: 57381425
TTD: D0Q1QY
 Compound Name PMID29671355-Compound-8 Patented [3]
MOA Inhibitor
Activity IC50 = 22800 nM
External Link
TTD: D0LN1T
 Compound Name PMID29671355-Compound-61 Patented [3]
MOA Inhibitor
Activity IC50 = 839.3 nM
External Link
TTD: D0JB4S
 Compound Name PMID29671355-Compound-44 Patented [3]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
CID: 72710871
TTD: D0N2DK
 Compound Name PMID29671355-Compound-56 Patented [3]
MOA Inhibitor
Activity IC50 = 28.7 nM
External Link
CID: 56965342
TTD: D0CH8Q
 Compound Name PMID29671355-Compound-67 Patented [3]
MOA Inhibitor
Activity IC50 = 10000 nM
External Link
CID: 60201048
TTD: D0M0RE
 Compound Name PMID29671355-Compound-31 Patented [3]
MOA Inhibitor
Activity IC50 = 0.6 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [3]
MOA Inhibitor
Activity IC50 = 10300 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [3]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [3]
MOA Inhibitor
Activity IC50 = 140 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [3]
MOA Inhibitor
Activity IC50 = 1310 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name RGFP966 Investigative [5]
Synonyms
RGFP-966
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 80 nM
External Link
CID: 56650312
TTD: D00HXX
 Compound Name droxinostat Investigative [6]
Synonyms
NS-41080; NS41080
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 568416
TTD: D00VXM
8B11: Acute ischemic stroke 7 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name PEG-bHb-CO Phase 2 [7]
Synonyms
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0A6LT
 Compound Name DM199 Phase 2 [8]
External Link
TTD: DS70MP
 Compound Name BIIB131 Phase 2 [9]
Synonyms
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007
    Click to Show/Hide
External Link
CID: 50898407
TTD: DEV2G0
 Compound Name BMS-986177 Phase 2 [10]
Synonyms
Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
    Click to Show/Hide
External Link
CID: 118277544
TTD: DB6XD8
 Compound Name SonoLysis Prolyse Phase 2 [11]
External Link
TTD: D08JGE
 Compound Name ACT017 Phase 1/2 [12]
External Link
TTD: DPG5T9
 Compound Name Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 Patented [13]
Synonyms
PMID27998201-Compound-16
    Click to Show/Hide
External Link
CID: 1720818
TTD: D0UX4J
References
Ref 1 METTL14 Promotes Ischemic Stroke-induced Brain Injury by Stabilizing HDAC3 Expression in an m6A-IGF2BP3 Mechanism. Cell Biochem Biophys. 2025 Jun;83(2):1897-1907. doi: 10.1007/s12013-024-01596-z. Epub 2024 Oct 25.
Ref 2 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
Ref 3 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 4 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
Ref 5 HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.
Ref 6 Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
Ref 9 ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health.
Ref 10 ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
Ref 11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
Ref 12 ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health.
Ref 13 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.